Arthur D. Little Announces Promotion of Seven New Partners as the Consultancy Continues Its Global Expansion
Arthur D. Little (ADL) today announced the promotion of seven of its consultants to the rank of Partner, in recognition of the expertise and depth of experience that each one brings to the company. These appointments represent a major milestone for ADL, with the company now boasting over 100 Partners within its global team. Over the past five years, ADL has doubled in size by pursuing a dynamic growth path, and one of the key tenets of its ongoing success is the development and promotion of its internal talent.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210310005042/en/
Arthur D. Little has reached the 100+ partners milestones, with the promotion of seven partners. (Photo: Business Wire)
The latest appointments to Partner are as follows:
- Matteo Ainardi, Partner, Automotive and Manufacturing (AMG) and Strategy & Organization (S&O) Practices. Matteo joined ADL in 2016 and currently leads the company’s global Aerospace & Defense Center of Competence. His main focus is on supporting clients in the A&D ecosystem, focusing on strategy definition, organizational redesign and innovation management.
- Lokesh Dadhich, Partner, Telecommunication, Information, Media & Electronics (TIME) and Operations Management (OM) Practices. Lokesh joined ADL in 2007 and is based out of the company’s Dubai office. His main areas of expertise are in Digital Strategy, Customer Experience, and Operations Excellence topics. He advises clients in the TIME industry and beyond on strategy, operations, and transformation challenges.
- Naoya Furuta, Partner, Operations Management (OM) Practice. Naoya joined ADL’s Tokyo office as a Manager in 2016, and has experience across multiple industries, with a particular focus on manufacturing and construction. His main areas of expertise include company-wide strategic planning, corporate management, corporate reform, M&A advisory and PMI.
- Trung Ghi, Partner, Energy & Utilities (ENUT) Practice. With more than 20 years of experience in the oil and gas industry, Trung currently leads ADL’s ENUT Practice in South-East Asia, and has been responsible for opening a number of key accounts. He has been a driving force in positioning ADL as a go-to management consulting firm within SEA’s energy sector.
- Max Scherr, Partner, Strategy & Organization (S&O) Practice. With over 20 years of experience in strategy consulting as a senior executive, Max joined ADL in 2018 and leads the company’s S&O Practice in its Vienna office. His specializations include Digital Transformation, Information Security, Growth and Corporate Strategy.
- Ben Thuriaux-Alemán, Partner, Energy & Utilities (ENUT) and Technology & Innovation Management (TIM) Practices. With over 20 years of consulting experience, Ben has played a major role in developing ADL’s TIM Practice, and currently runs the company’s Global Innovation Excellence Benchmarking diagnostic. His particular focus is on aligning innovation with corporate strategy, and working on national innovation initiatives.
- Marten Zieris, Partner, Strategy & Organization (S&O) Practice. Marten joined ADL in 2010 and is based out of its Frankfurt office. He is responsible for the company’s competence center “Organization & Transformation” in Central Europe and supports international clients in large-scale transformations end to end, “from concept development to implementation”. Marten also has a specialist focus on consumer products businesses.
Ignacio García Alves, Chairman and CEO of Arthur D. Little, comments: “I would like to congratulate these new Partners – and welcome them as the first members of ADL’s ‘Generation 100’! Each promotion is richly deserved and a recognition of the vital contribution that each Partner makes to our company. At ADL, we strive to employ and develop consultants who are both entrepreneurs and team players, and aspire to deliver consultancy at the highest level – as such, having over 100 Partners within ADL truly is a momentous achievement.”
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210310005042/en/
Contact information
Sue Glanville/Cate Bonthuys
Catalyst Comms
+44 7715 817589
info@catalystcomms.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom